Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,835 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer.
DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin E, Capanna T, Ciardella M, Doyle-Lindrud S, Goodwin S, Fontaine M, Adams N, Williams A, Schwartz M, Winchell G, Wickersham K, Deutsch P, Yao SL. DiPaola RS, et al. Among authors: rubin e. J Clin Oncol. 2002 Apr 1;20(7):1874-9. doi: 10.1200/JCO.2002.07.001. J Clin Oncol. 2002. PMID: 11919247 Clinical Trial.
A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies.
Thalasila A, Poplin E, Shih J, Dvorzhinski D, Capanna T, Doyle-Lindrud S, Beers S, Goodin S, Rubin E, DiPaola RS. Thalasila A, et al. Among authors: rubin e. Cancer Chemother Pharmacol. 2003 Aug;52(2):119-24. doi: 10.1007/s00280-003-0644-6. Epub 2003 May 24. Cancer Chemother Pharmacol. 2003. PMID: 12768320 Clinical Trial.
Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies.
DiPaola RS, Rafi MM, Vyas V, Toppmeyer D, Rubin E, Patel J, Goodin S, Medina M, Medina P, Zamek R, Zhang C, White E, Gupta E, Hait WN. DiPaola RS, et al. Among authors: rubin e. J Clin Oncol. 1999 Jul;17(7):2213-8. doi: 10.1200/JCO.1999.17.7.2213. J Clin Oncol. 1999. PMID: 10561278 Clinical Trial.
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
Rubin EH, de Alwis DP, Pouliquen I, Green L, Marder P, Lin Y, Musanti R, Grospe SL, Smith SL, Toppmeyer DL, Much J, Kane M, Chaudhary A, Jordan C, Burgess M, Slapak CA. Rubin EH, et al. Clin Cancer Res. 2002 Dec;8(12):3710-7. Clin Cancer Res. 2002. PMID: 12473580 Clinical Trial.
1,835 results